SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-24-001894
Filing Date
2024-01-08
Accepted
2024-01-08 16:05:32
Documents
14
Period of Report
2024-01-08
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea191339-8k_immucell.htm   iXBRL 8-K 26350
2 PRESS RELEASE OF IMMUCELL CORPORATION DATED JANUARY 8, 2024 ea191339ex99-1_immucell.htm EX-99.1 20872
3 GRAPHIC ex99-1_001.jpg GRAPHIC 2680
  Complete submission text file 0001213900-24-001894.txt   228899

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE iccc-20240108.xsd EX-101.SCH 3015
5 XBRL LABEL FILE iccc-20240108_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE iccc-20240108_pre.xml EX-101.PRE 22359
8 EXTRACTED XBRL INSTANCE DOCUMENT ea191339-8k_immucell_htm.xml XML 3206
Mailing Address 56 EVERGREEN DRIVE PORTLAND ME 04103
Business Address 56 EVERGREEN DR PORTLAND ME 04103 2078782770
IMMUCELL CORP /DE/ (Filer) CIK: 0000811641 (see all company filings)

IRS No.: 010382980 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-12934 | Film No.: 24520073
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)